Wolfe Research Initiates Thermo Fisher with Outperform Rating and $535 Target

Key Facts

In a move reflecting optimism within the healthcare equipment sector, Wolfe Research has initiated coverage on Thermo Fisher Scientific with an Outperform rating. Analysts set a price target of $535.00, suggesting an approximate 8% upside potential from current levels. This valuation is underpinned by a 20x P/E multiple applied to the firm's 2027 EPS estimates, aligning with prevailing sector standards.

This bullish initiation comes as the life sciences tools sector shows relative stability compared to peers; for instance, Danaher (DHR) recently reported quarterly results that beat expectations, bolstering confidence in a recovery for lab capital spending. Per market data, Thermo Fisher's stock is trading at levels reflecting its diversified business resilience, while recent peer earnings reports suggest a gradual improvement in operating margins across the industry.

Investors should monitor the stock's performance following this initiation, with a close eye on critical economic catalysts such as the U.S. Core PCE Price Index scheduled for release on May 28, 2026. Additionally, the Fed Logan speech on May 27 may provide further clarity on the interest rate trajectory, which remains a pivotal factor for the biotech clients served by Thermo Fisher.